Showing results (151-160 of 163) with videos related to

Sort By:
Pageof 17
Infection|January 17, 2023
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trialMatthew G Johnson, Julie M Strizki, Michelle L Brown, et al.
TAG. Theoretical and Applied Genetics. Theoretische Und Angewandte Genetik|June 23, 2006
The first gene-based map of Lupinus angustifolius L.-location of domestication genes and conserved synteny with Medicago truncatulaMatthew N Nelson, Huyen T T Phan, Simon R Ellwood, et al.
Clinical Trials (London, England)|March 3, 2025
Impact of differences between interim and post-interim analysis populations on outcomes of a group sequential trial: Example of the MOVe-OUT studyYoseph Caraco, Matthew G Johnson, Joseph A Chiarappa, et al.
Microbiology Spectrum|February 1, 2024
Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT)Matthew G Johnson, Julie M Strizki, Erin Jensen, et al.
Orphanet Journal of Rare Diseases|September 26, 2023
The International X-Linked Hypophosphatemia (XLH) Registry: first interim analysis of baseline demographic, genetic and clinical dataGema Ariceta, Signe Sparre Beck-Nielsen, Annemieke M Boot, et al.
NEJM Evidence|February 6, 2024
Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized AdultsYoseph Caraco, Gordon E Crofoot, Pablo Andres Moncada, et al.
Plos One|March 20, 2026
The lived experience of adolescents with X-linked hypophosphataemia treated with burosumab at end of skeletal growth: a mixed-methods analysisVrinda Saraff, Pedro Arango Sancho, Justine Bacchetta, et al.
Calcified Tissue International|January 23, 2021
Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked HypophosphatemiaRaja Padidela, Michael P Whyte, Francis H Glorieux, et al.
The New England Journal of Medicine|December 16, 2021
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized PatientsAngélica Jayk Bernal, Monica M Gomes da Silva, Dany B Musungaie, et al.
The Journal of Allergy and Clinical Immunology|November 14, 2021
Thunderstorm asthma in seasonal allergic rhinitis: The TAISAR studyJo A Douglass, Caroline Lodge, Samantha Chan, et al.
Pageof 17